DelveInsight’s “Von Willebrand Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Von Willebrand Disease, historical and forecasted epidemiology as well as the Von Willebrand Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Von Willebrand Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Von Willebrand Disease Market Forecast
Some of the key facts of the Von Willebrand Disease Market Report:
The Von Willebrand Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In 2023, the overall number of diagnosed prevalent cases of VWD in the United States was estimated to be approximately 13,000, with projections indicating an anticipated increase at a moderate compound annual growth rate (CAGR) throughout the study period spanning from 2019 to 2032.
Women comprise the majority, constituting approximately 55%, of diagnosed prevalent cases of VWD in the US, exceeding 7,000 cases in 2023.
In 2023, VWD Type 2 and Type 3 collectively represented approximately 11% and 6% of all diagnosed prevalent cases of VWD in the US, respectively. Meanwhile, VWD Type 1 accounted for the majority, comprising around 83% of cases alone in 2023.
Key Von Willebrand Disease Companies: Octapharma, Grifols Therapeutics LLC, CSL Behring, Margaret Ragni, Shire, Archemix Corp., and others
Key Von Willebrand Disease Therapies: Wilate, plasma-derived FVIII/VWF concentrate, Biostate®, Voncento, Oprelvekin, Interleukin 11, IL-11, Alphanate SD/HT, rVWF, ARC1779, and others
The Von Willebrand Disease epidemiology based on gender analyzed that females are affected more as compared to males, in case of Von Willebrand disease (VWD)
The Von Willebrand Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Von Willebrand Disease pipeline products will significantly revolutionize the Von Willebrand Disease market dynamics.
Von Willebrand Disease Overview
Von Willebrand disease (VWD) is a genetic blood disorder characterized by a deficiency or dysfunction of von Willebrand factor (VWF), a protein involved in blood clotting. VWF helps platelets stick together and adhere to blood vessel walls, promoting clot formation and preventing excessive bleeding.
Get a Free sample for the Von Willebrand Disease Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/von-willebrand-disease-vwd-market
Von Willebrand Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Von Willebrand Disease Epidemiology Segmentation:
The Von Willebrand Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalence of Von Willebrand Disease
Prevalent Cases of Von Willebrand Disease by severity
Gender-specific Prevalence of Von Willebrand Disease
Diagnosed Cases of Episodic and Chronic Von Willebrand Disease
Download the report to understand which factors are driving Von Willebrand Disease epidemiology trends @ Von Willebrand Disease Epidemiology Forecast
Von Willebrand Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Von Willebrand Disease market or expected to get launched during the study period. The analysis covers Von Willebrand Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Von Willebrand Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Von Willebrand Disease Therapies and Key Companies
Wilate: Octapharma
plasma-derived FVIII/VWF concentrate: Grifols Therapeutics LLC
Biostate®: CSL Behring
Voncento: CSL Behring
Oprelvekin, Interleukin 11, IL-11: Margaret Ragni
Alphanate SD/HT: Grifols Biologicals, LLC
rVWF: Baxalta now part of Shire
ARC1779: Archemix Corp.
Discover more about therapies set to grab major Von Willebrand Disease market share @ Von Willebrand Disease Treatment Landscape
Von Willebrand Disease Market Drivers
Rise in Von Willebrand Disease (VWD) market is attributed to several factors such as increasing prevalence, evolving research, more diagnostic tests, and novel systemic therapies.
Von Willebrand Disease Market Barriers
Due to lack of competitors in Von Willebrand Disease, there is a substantial market opportunity for key players to develop Von Willebrand Diseasetargeting therapies.
Scope of the Von Willebrand Disease Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Von Willebrand Disease Therapeutic Assessment: Von Willebrand Disease current marketed and Von Willebrand Disease emerging therapies
Von Willebrand Disease Market Dynamics: Von Willebrand Disease market drivers and Von Willebrand Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Von Willebrand Disease Unmet Needs, KOL’s views, Analyst’s views, Von Willebrand Disease Market Access and Reimbursement
To know more about Von Willebrand Disease companies working in the treatment market, visit @ Von Willebrand Disease Clinical Trials and Therapeutic Assessment
Table of Contents
1. Von Willebrand Disease Market Report Introduction
2. Executive Summary for Von Willebrand Disease
3. SWOT analysis of Von Willebrand Disease
4. Von Willebrand Disease Patient Share (%) Overview at a Glance
5. Von Willebrand Disease Market Overview at a Glance
6. Von Willebrand Disease Disease Background and Overview
7. Von Willebrand Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Von Willebrand Disease
9. Von Willebrand Disease Current Treatment and Medical Practices
10. Von Willebrand Disease Unmet Needs
11. Von Willebrand Disease Emerging Therapies
12. Von Willebrand Disease Market Outlook
13. Country-Wise Von Willebrand Disease Market Analysis (2019–2032)
14. Von Willebrand Disease Market Access and Reimbursement of Therapies
15. Von Willebrand Disease Market Drivers
16. Von Willebrand Disease Market Barriers
17. Von Willebrand Disease Appendix
18. Von Willebrand Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
